RU2016118008A - Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака - Google Patents
Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака Download PDFInfo
- Publication number
- RU2016118008A RU2016118008A RU2016118008A RU2016118008A RU2016118008A RU 2016118008 A RU2016118008 A RU 2016118008A RU 2016118008 A RU2016118008 A RU 2016118008A RU 2016118008 A RU2016118008 A RU 2016118008A RU 2016118008 A RU2016118008 A RU 2016118008A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- cbp
- carcinoma
- cell
- paragraphs
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 201000009030 Carcinoma Diseases 0.000 claims 9
- 230000001093 anti-cancer Effects 0.000 claims 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 201000004253 NUT midline carcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 235000008753 Papaver somniferum Nutrition 0.000 claims 1
- 240000001090 Papaver somniferum Species 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 201000000331 Testicular germ cell cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000011186 acute T cell leukemia Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000007180 bile duct carcinoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000000860 cochlear nerve Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 201000004123 pineal gland cancer Diseases 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Claims (22)
1. Способ лечения или замедления прогрессирования рака у пациента, включающий введение пациенту эффективного количества ингибитора бромодомена CBP/EP300.
2. Способ усиления иммунной функции у пациента, имеющего рак, включающий введение пациенту эффективного количества ингибитора бромодомена CBP/EP300.
3. Способ по п. 1 или 2, где T-клетки CD8 у пациента имеют усиленную активность примирования, активационную, пролиферативную и/или цитолитическую активность до введения ингибитора бромодомена CBP/EP300.
4. Способ по п.3, где количество T-клеток CD8 повышено относительно до введения ингибитора бромодомена CBP/EP300.
5. Способ по любому из пп.3 и 4, где T-клетки CD8 являются анитиген-специфическими T-клетками CD8.
6. Способ по любому из пп.1-5, где рак имеет повышенный уровень T-клеточной инфильтрации.
7. Способ по любому из пп. 1-6, где рак ассоциирован с увеличенной внутриопухолевой плотностью Treg клеток.
8. Способ по любому из пп.1-7, где рак выбирают из невриномы слухового нерва, острого лейкоза, острого лимфоцитарного лейкоза, острого миелоцитарного лейкоза, острого t-клеточного лейкоза, базальноклеточной карциномы, карциномы желчных протоков, рака мочевого пузыря, рака головного мозга, рака молочной железы, бронхогенной карциномы, рака шейки матки, хондросаркомы, хордомы, хориокарциномы, хронического лейкоза, хронического лимфоцитарного лейкоза, хронического миелоцитарного лейкоза, хронического миелогенного лейкоза, рака ободочной кишки, колоректальногог рака, краниофарингеомы, цистаденокарциномы, диффузной крупно B-клеточной лимфомы, диспролиферативных изменений, эмбриональной карциномы, рака эндометрия, эндотелиосаркомы, эпендимомы, эпителиальной карциномы, эритролейкемии, рака пищевода, рака молочной железы, положительного по эстрогеновым рецепторам, эссенциальной тромбоцитемии, опухоли Юинга, фибросаркомы, фолликулярной лимфомы, рака зародышевых клеток яичек, глиомы, глиобластомы, глиосаркомы, болезни тяжелых цепей, рака головы и шеи, гемангиобластомы, гепатомы, печеночно-клеточного рака, гормон-нечувствительного рака предстательной железы, лейомиосаркомы, лейкоза, липосаркомы, рака легкого, лимфангиоэндотелиосаркомы, лимфангиосаркомы, лимфобластного лейкоза, лимфомы, лимфоидных злокачественных новообразований T-клеточного или B-клеточного происхождения, медуллярной карциномы, медуллобластомы, меланомы, менингиомы, мезотелиомы, множественной миеломы, миелогенного лейкоза, миеломы, миксосаркомы, нейробластомы карциномы срединной линии NUT (NMC), немелкоклеточного рака легкого (NSCLC), олигодендроглиомы, рака полости рта, остеогенной саркомы, рака яичника, рака поджелудочной железы, папиллярных аденокарцином, капиллярной карциномы, пинеаломы, истинной полицитемии, рака предстательной железы, рака прямой кишки, почечно-клеточной карциномы, ретинобластомы, рабдомиосаркомы, саркомы, карциномы сальных желез, семиномы, рака кожи, мелкоклеточной карциномы легкого, солидных опухолей (карцином и сарком), мелкоклеточного рака легкого, рака желудка, плоскоклеточной карциномы, синовиомы, карциномы потовых желез, рака щитовидной железы, макроглобулинемии Вальденстрема, опухолей яичек, рака матки и опухоли Вильмса.
9. Способ по любому из пп. 1-8, где раком является меланома, NSCLC, рак почки, яичника, ободочной кишки, поджелудочной железы, печеночно-клеточный рак или рак молочной железы.
10. Способ по любому из пп. 1-9, где раком является рак NSCLC, яичника, поджелудочной железы, печеночно-клеточный рак или рак молочной железы.
11. Способ по любому из пп. 1-8, где раком является меланома, NSCLC, или почечно-клеточная карцинома.
12. Способ по любому из пп. 1-11, где ингибитор бромодомена CBP/EP300 ингибирует CBP.
13. Способ по любому из пп. 1-11, где ингибитор бромодомена CBP/EP300 ингибирует EP300.
14. Способ по любому из пп. 1-13, где способ подавляет функцию Treg.
15. Способ по любому из пп. 1-14, где способ снижает Т-клеточное истощение T-клеток CD8+.
16. Способ по любому из пп. 1-15, где ингибитор бромодомена CBP/EP300 не связывается с доменом HAT CBP и/или EP300.
17. Способ по любому из пп. 1-16, где пациентом является человек.
18. Ингибитор бромодомена CBP/EP300 для применения в лечении или диагностике в медицине, включая терапию и/или лечение рака.
19. Способ выбора противоракового соединения, включающий определение, является ли тестируемое соединение соединением ингибитором бромодоменa CBP/EP300, где тестируемое соединение, которое является соединением ингибитором бромодомена CBP/EP300, выбирают в качестве противоракового соединения.
20. Способ по п.19, дополнительно включающий определение того, связывается ли тестируемое соединение с HAT доменом CBP и/или EP300, где тестируемое соединение, которое не связывается с HAT доменом CBP и/или EP300, выбирают в качестве противоракового соединения.
21. Способ по п.19 или 20, дополнительно включающий определение, подавляет ли тестируемое соединение Treg функцию, где тестируемое соединение, которое подавляет Treg функцию, выбирают в качестве противоракового соединения.
22. Способ по любому из пп.19-21, дополнительно включающий определение, снижает ли тестируемое соединение T-клеточное истощение T-клеток CD8+, где тестируемое соединение, которое снижает T-клеточное истощение T-клеток CD8+, выбирают в качестве противоракового соединения.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890041P | 2013-10-11 | 2013-10-11 | |
| US61/890,041 | 2013-10-11 | ||
| PCT/US2014/060147 WO2015054642A2 (en) | 2013-10-11 | 2014-10-10 | Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016118008A true RU2016118008A (ru) | 2017-11-16 |
| RU2016118008A3 RU2016118008A3 (ru) | 2018-07-25 |
Family
ID=52813753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016118008A RU2016118008A (ru) | 2013-10-11 | 2014-10-10 | Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160317632A1 (ru) |
| EP (1) | EP3054966A4 (ru) |
| JP (1) | JP2016534044A (ru) |
| KR (1) | KR20160060765A (ru) |
| CN (1) | CN105979958A (ru) |
| AU (1) | AU2014331697A1 (ru) |
| BR (1) | BR112016007891A2 (ru) |
| CA (1) | CA2926946A1 (ru) |
| IL (1) | IL245016A0 (ru) |
| MX (1) | MX2016004570A (ru) |
| RU (1) | RU2016118008A (ru) |
| SG (1) | SG11201602815YA (ru) |
| WO (1) | WO2015054642A2 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| CN103037865B (zh) | 2010-05-14 | 2014-10-29 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的化合物 |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| ES2985394T3 (es) | 2015-05-29 | 2024-11-05 | Merck Sharp & Dohme Llc | Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer |
| PE20181068A1 (es) * | 2015-10-02 | 2018-07-04 | Dana Farber Cancer Inst Inc | Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control |
| JP6859954B2 (ja) * | 2015-11-04 | 2021-04-14 | アステラス製薬株式会社 | ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物 |
| AU2017302554A1 (en) | 2016-07-25 | 2019-01-31 | Epizyme, Inc. | CREBBP related cancer therapy |
| EP3752250B1 (en) | 2018-02-16 | 2022-08-03 | Constellation Pharmaceuticals, Inc. | P300/cbp hat inhibitors |
| DK3752497T3 (da) | 2018-02-16 | 2024-09-30 | Constellation Pharmaceuticals Inc | P300/cbp-hat-hæmmere |
| TW202028222A (zh) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| EP3986470A4 (en) * | 2019-06-18 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE TARGET BROMO/ACETYL PROTEINS AND THEIR USES |
| CN110170052B (zh) * | 2019-06-21 | 2020-07-10 | 复旦大学 | Cbp-p300抑制剂在肠道损伤疾病中的应用 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| CA3153456A1 (en) | 2019-10-02 | 2021-04-08 | Stefanie Fluckiger-Mangual | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN110938630B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人b3gnt5基因的用途及相关产品 |
| JP2023528223A (ja) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 |
| EP4171557A1 (en) | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| CA3183982A1 (en) * | 2020-06-25 | 2021-12-30 | Stefanie Fluckiger-Mangual | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120028912A1 (en) * | 2000-02-22 | 2012-02-02 | J.David Gladstone Institute | Methods of modulating bromodomains |
| WO2008157680A2 (en) * | 2007-06-21 | 2008-12-24 | The Wistar Institute | Methods and compositions for modulating p300/cbp activity |
| EP2239264A4 (en) * | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMORAL MEDIUM |
| GB201020015D0 (en) * | 2010-11-25 | 2011-01-12 | Glaxo Group Ltd | Method of treatment |
| AU2012220620A1 (en) * | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
| WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
| EP2861255B1 (en) * | 2012-06-19 | 2019-10-09 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
| EP3193866A1 (en) * | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
-
2014
- 2014-10-10 EP EP14853063.7A patent/EP3054966A4/en not_active Withdrawn
- 2014-10-10 CN CN201480067309.0A patent/CN105979958A/zh active Pending
- 2014-10-10 AU AU2014331697A patent/AU2014331697A1/en not_active Abandoned
- 2014-10-10 WO PCT/US2014/060147 patent/WO2015054642A2/en not_active Ceased
- 2014-10-10 RU RU2016118008A patent/RU2016118008A/ru not_active Application Discontinuation
- 2014-10-10 JP JP2016521742A patent/JP2016534044A/ja not_active Withdrawn
- 2014-10-10 BR BR112016007891A patent/BR112016007891A2/pt not_active IP Right Cessation
- 2014-10-10 KR KR1020167011914A patent/KR20160060765A/ko not_active Withdrawn
- 2014-10-10 SG SG11201602815YA patent/SG11201602815YA/en unknown
- 2014-10-10 MX MX2016004570A patent/MX2016004570A/es unknown
- 2014-10-10 CA CA2926946A patent/CA2926946A1/en not_active Abandoned
-
2016
- 2016-04-10 IL IL245016A patent/IL245016A0/en unknown
- 2016-04-11 US US15/095,985 patent/US20160317632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014331697A1 (en) | 2016-05-05 |
| AU2014331697A9 (en) | 2016-05-26 |
| SG11201602815YA (en) | 2016-05-30 |
| JP2016534044A (ja) | 2016-11-04 |
| IL245016A0 (en) | 2016-05-31 |
| BR112016007891A2 (pt) | 2017-12-05 |
| MX2016004570A (es) | 2016-09-08 |
| CA2926946A1 (en) | 2015-04-16 |
| WO2015054642A9 (en) | 2016-04-28 |
| EP3054966A2 (en) | 2016-08-17 |
| WO2015054642A2 (en) | 2015-04-16 |
| CN105979958A (zh) | 2016-09-28 |
| US20160317632A1 (en) | 2016-11-03 |
| RU2016118008A3 (ru) | 2018-07-25 |
| KR20160060765A (ko) | 2016-05-30 |
| WO2015054642A3 (en) | 2015-06-04 |
| EP3054966A4 (en) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016118008A (ru) | Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака | |
| JP2016534044A5 (ru) | ||
| Xu et al. | Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study | |
| JP2017506264A5 (ru) | ||
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| Chi et al. | Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort | |
| RU2017119820A (ru) | Композиции и способы профилактики и лечения злокачественных новообразований | |
| WO2017024032A3 (en) | Compositions and methods for treating cancers associated with etbr activation | |
| IL278423B2 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| RU2015118135A (ru) | Содержащие заместители бензольные соединения | |
| MX388166B (es) | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| JP2016512831A5 (ru) | ||
| Vergote et al. | A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| Mukherji et al. | New treatment developments applied to elderly patients with advanced prostate cancer | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| BR112014018374A8 (pt) | Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica | |
| Xu | Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer | |
| WO2014087240A3 (en) | Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis | |
| Kim et al. | Outcomes of palliative weekly low-dose gemcitabine-cisplatin chemotherapy in anthracycline-and taxane-pretreated metastatic breast cancer patients | |
| Ramalingam et al. | Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003) | |
| EA201992130A1 (ru) | Usl-1 для применения в лечении злокачественной опухоли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181113 |